Potential treatment target in fatty liver disease identified

Metabolic dysfunction-associated steatotic liver disease (MASLD) can cause more serious liver conditions, such as liver failure. A new study, led by Lund University in Sweden, presents new data that may lead to better disease management and prevention in the future. The international research team identified an altered expression of specific genes in samples from individuals with obesity, MASLD and liver fibrosis.